Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20961003 | 0.84 | BCHE (0.47) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL12793892 | 0.82 | BCHE (0.51) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28262599 | 0.81 | BCHE (0.55) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22517725 | 0.81 | BCHE (0.47) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3504583 | 0.79 | BCHE (0.46) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3504585 | 0.79 | BCHE (0.46) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16311866 | 0.79 | CHRM2 (0.56) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL23785745 | 0.78 | CHRM2 (0.57) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22101385 | 0.78 | CHRNA7 (0.54) | BCHEMEN1KMT2AHTR3EHTR3B | |
| SCHEMBL28391085 | 0.78 | SLC18A3 (0.55) | BCHECHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | OPKO PHARMACEUTICALS, LLC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009620-A1 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY | SI, GYS1, UGGT1 | BCHE 1678/4885CHRM2 1384/4885CHRM4 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.